Published January 31, 2026 | Version v2
Data paper Open

Modeling Nonlinear Pharmacokinetics: Clinical v. Anecdotal Data (LGD-4033)

Authors/Creators

  • 1. ROR icon St. John's University

Files

Modeling Nonlinear Pharmacokinetics (UPDATED).pdf

Files (3.7 MB)

Additional details

Additional titles

Subtitle (English)
Why Dosage Is Not the Same as Exposure!

Dates

Submitted
2026-01-27

Software

Repository URL
https://github.com/Nathaniel-Coulter/Pharmacokinetics
Programming language
Python

References

  • Basaria, S., Collins, L., Dillon, E. L., Orwoll, K., Storer, T. W., Miciek, R., Ulloor, J., Zhang, A., Zientek, H., & Bhasin, S. (2013). The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral selective androgen receptor modulator, in healthy young men. Journal of Gerontology: Biological Sciences and Medical Sciences, 68(1), 87–95. https://doi.org/10.1093/gerona/gls078
  • Boston University & Ligand Pharmaceuticals. (2013). Safety and tolerability of LGD-4033, a novel non-steroidal oral selective androgen receptor modulator (SARM), in healthy men: Phase I multiple ascending dose study. Journal of Gerontology: Biological Sciences and Medical Sciences, 68(1), 87–95.
  • Wagener, F., Guddat, S., Görgens, C., Angelis, Y. S., Petrou, M., Lagojda, A., Kühne, D., & Thevis, M. (2022). Investigations into the elimination profiles and metabolite ratios of micro-dosed selective androgen receptor modulator LGD-4033 for doping control purposes. Analytical and Bioanalytical Chemistry, 414, 1151–1162. https://doi.org/10.1007/s00216-021-03740-7
  • Labban, H., Kwait, B., Paracha, A., Islam, M., & Kim, D. O. (2024). LGD-4033 and a case of drug-induced liver injury: Exploring the clinical implications of off-label selective androgen receptor modulator use in healthy adults. Cureus, 16(9), e69601. https://doi.org/10.7759/cureus.69601
  • BenchChem Technical Support Team. (2025). A method to refine LGD-4033 treatment protocols to minimize side effects. Technical support document. Investigational compound; not approved for human use.
  • Cardaci, T. D., Machek, S. B., Wilburn, D. T., Helisone, J. L., Harris, D. R., Cintineo, H. P., & Willoughby, D. S. (2022). LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report. Experimental Physiology, 107(12), 1467–1476. https://doi.org/10.1113/EP090741